Dr. Reddy’s Partners with Takeda for Dengue Vaccine Distribution in India
Dr Reddys Laboratories Ltd · Press Release · 18 Sept 2026, 2:30 pm
Dr. Reddy’s Partners with Takeda for Dengue Vaccine Distribution in India Dr. Reddy's Laboratories entered into an exclusive agreement on 18th Sep'26 with Takeda Biopharmaceuticals India to distribute and market Qdenga®, India’s first CDSCO-approved dengue vaccine, across the domestic private market for individuals aged 4–60 years. Takeda will handle manufacturing, importation, and public market rights, retaining legal ownership. The agreement entails no upfront consideration or milestone payments. The vaccine is anticipated to launch in H1'27, strengthening Dr. Reddy's domestic vaccines portfolio amid rising dengue prevalence.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 05 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
